Wearable Injectors Market Size is valued at USD 4.16 Bn in 2023 and is predicted to reach USD 7.87 Bn by the year 2031 at a 8.44% CAGR during the forecast period for 2024-2031.
Wearable injectors, sometimes called patch pumps, are small drug delivery systems intended to continuously administer medications for extended periods. They are placed briefly on the skin to quickly and safely administer viscous medications in large quantities via the body's subcutaneous tissues. The apparatus consists of a reservoir for medication storage, a cannula for administering medicine to tissues, and a driving mechanism to provide the appropriate medication dosage. They often come in off-body and on-body injector varieties.
The increased occurrence of chronic diseases such as oncological, neurological, and autoimmune disorders is one of the key reasons driving the market's rise. Additionally, the growing desire for minimally invasive (MI) treatment alternatives among patients and the ageing population, which makes people more susceptible to certain diseases, is fueling market growth. Since they provide excellent disease control with a low risk of dose mistakes and needle stick injuries, injectors that may be used at home and by the users themselves are also growing in popularity.
Numerous product advancements, including Bluetooth, wireless communication, and passive warning systems with injectors, are also growth-promoting factors. Additional factors are projected to fuel market expansion, including extensive research and development initiatives and significant improvements in healthcare infrastructure, particularly in emerging countries.
Some Major Key Players In The Wearable Injectors Market:
The wearable injectors market is divided on the basis of type of device, usability and therapeutic area. Based on the type of device, the market is segmented as Patch Pump / Injectors and Infusion Pump / Injectors. As per the usability, the market is segmented into Disposable and Reusable. On the basis of therapeutic area, the market is categorized into Autoimmune Disorders, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders and Other Disorders.
The oncological disorders category is expected to hold a major share of the global wearable injectors market in 2024 because cancer is becoming more common, and individuals are increasingly choosing to self-administer their medications. According to the Canadian Cancer Society, about 7% of Canadian men will develop lung and bronchus cancer, and about 5% will die. More people are preferring to self-administer their drugs as the prevalence of cancer rises. The market is also anticipated to grow as a result of technological advancements and the accessibility of wearable injectors for the management of these conditions.
The infusion pump/injectors segment is projected to grow rapidly in the global wearable injectors market. Patients can wear wearable infusion pumps, small, lightweight devices with skin-accessible cannulas on their belts. The term "off-body injectors" is another name for these medication delivery systems. These are perfect for patients who need continuous or intermittent infusions over a long length of time since they let them move around freely while receiving treatment. Most insulin pumps are belt-mounted, with a line running from the pump to the infusion set and resting in the fatty tissue beneath the skin.
The North American wearable injectors market is expected to register the maximum market share in terms of revenue. The region's jurisdiction is expanding due to the huge biologics pipeline and the rising burden of chronic diseases. Additionally, it is anticipated that wearable injectors will become more popular in the region due to their great performance and simplicity of use in treating certain diseases, such as autoimmune disorders, cancer, and hematologic disorders. In addition, Asia-Pacific is expected to grow at the quickest rate, driven by the expansion of improved healthcare facilities and the development of healthcare infrastructure. Additionally, the region's domain is expanding due to government programs supporting the use of wearable injectors, rising healthcare costs, and an increase in the number of elderly people.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 4.16 Bn |
| Revenue Forecast In 2031 | USD 7.87 Bn |
| Growth Rate CAGR | CAGR of 8.44% from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn, volume (units) and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of device, Usability, Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | CCBio, CeQur, Debiotech, E3D Elcam Drug Delivery Devices, Eli Lilly, Enable Injections, Gerresheimer, Insulet, Medtronic, Medtrum Technologies, Pharmasense, Roche, Sonceboz, Weibel CDS, West Pharmaceuticals and SOOIL Development, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Elcam Drug Delivery Devices (Israel), Recipharm AB. (U.K), Stevanato Group (Italy), Sorrel Medical (Israel), and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Wearable Injectors Market By Type of Device
Wearable Injectors Market By Usability
Wearable Injectors Market By Therapeutic Area
Wearable Injectors Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Wearable Injectors Market Snapshot
Chapter 4. Global Wearable Injectors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type of Device Estimates & Trend Analysis
5.1. By Type of Device, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of Device:
5.2.1. Patch Pump / Injectors
5.2.2. Infusion Pump / Injectors
Chapter 6. Market Segmentation 2: By Usability Estimates & Trend Analysis
6.1. By Usability & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Usability:
6.2.1. Disposable
6.2.2. Reusable
Chapter 7. Market Segmentation 3: By Therapeutic Area Estimates & Trend Analysis
7.1. By Therapeutic Area & Market Share, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapeutic Area:
7.2.1. Autoimmune Disorders
7.2.2. Cardiovascular Disorders
7.2.3. Metabolic Disorders
7.2.4. Neurological Disorders
7.2.5. Oncological Disorders
7.2.6. Other Disorders
Chapter 8. Wearable Injectors Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Wearable Injectors Market revenue (US$ Million) estimates and forecasts By Type of Device, 2019-2031
8.1.2. North America Wearable Injectors Market revenue (US$ Million) estimates and forecasts By Usability, 2019-2031
8.1.3. North America Wearable Injectors Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2031
8.1.4. North America Wearable Injectors Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Wearable Injectors Market revenue (US$ Million) By Type of Device, 2019-2031
8.2.2. Europe Wearable Injectors Market revenue (US$ Million) By Usability, 2019-2031
8.2.3. Europe Wearable Injectors Market revenue (US$ Million) By Therapeutic Area, 2019-2031
8.2.4. Europe Wearable Injectors Market revenue (US$ Million) by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Wearable Injectors Market revenue (US$ Million) By Type of Device, 2019-2031
8.3.2. Asia Pacific Wearable Injectors Market revenue (US$ Million) By Usability, 2019-2031
8.3.3. Asia Pacific Wearable Injectors Market revenue (US$ Million) By Therapeutic Area, 2019-2031
8.3.4. Asia Pacific Wearable Injectors Market revenue (US$ Million) by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Wearable Injectors Market revenue (US$ Million) By Type of Device, (US$ Million) 2019-2031
8.4.2. Latin America Wearable Injectors Market revenue (US$ Million) By Usability, (US$ Million) 2019-2031
8.4.3. Latin America Wearable Injectors Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2019-2031
8.4.4. Latin America Wearable Injectors Market revenue (US$ Million) by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Wearable Injectors Market revenue (US$ Million) By Type of Device, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Wearable Injectors Market revenue (US$ Million) By Usability, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Wearable Injectors Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Wearable Injectors Market revenue (US$ Million) by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. CCBio
9.2.2. CeQur
9.2.3. Debiotech
9.2.4. E3D Elcam Drug Delivery Devices
9.2.5. Eli Lilly
9.2.6. Enable Injections
9.2.7. Gerresheimer
9.2.8. Insulet
9.2.9. Medtronic
9.2.10. Medtrum Technologies
9.2.11. Pharmasense
9.2.12. Roche
9.2.13. Sonceboz
9.2.14. Weibel CDS
9.2.15. West Pharmaceuticals
9.2.16. SOOIL Development
9.2.17. Becton, Dickinson and Company
9.2.18. Johnson & Johnson Services, Inc.
9.2.19. Elcam Drug Delivery Devices (Israel)
9.2.20. Recipharm AB. (U.K)
9.2.21. Stevanato Group (Italy)
9.2.22. Sorrel Medical (Israel)
9.2.23. Others